Picture of Veracyte logo

VCYT — Veracyte News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Veracyte Inc expected to post a loss of 24  cents a share - Earnings Preview

* Veracyte Inc  VCYT.OQ   VCYT.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 3. 
    * The South San Francisco California-based  company is
expected to
report  a 69.8% increase in revenue to $62.325 million from
$36.7 million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Veracyte Inc is for
a
loss of 24 cents per share. For the same quarter last year, the
company reported a loss of 11 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Veracyte
Inc is
$37.5​, above​ its last closing price of $21.34. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.18       -0.16      -0.15     Beat    6.9
 Sep. 30 2021  -0.17       -0.16      -0.20     Missed  -21.2
 Jun. 30 2021  -0.25       -0.25      -0.13     Beat    48.4​
 Mar. 31 2021  -0.12       -0.12      -0.11     Beat    8.3
 ​​Dec.        -0.10       -0.11      -0.14     Missed  -30.2
 31 2020                                                
 Sep. 30 2020  -0.20       -0.21      -0.08     Beat    61.9​
 Jun. 30 2020  -0.27       -0.24      -0.22     Beat    9.8
 Mar. 31 2020  -0.19       -0.20      -0.24     Missed  -22
 This summary was machine generated April 29 at 20:51 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Veracyte

See all news